H1450000

Hyoscine butylbromide

European Pharmacopoeia (EP) Reference Standard

Synonym(s):
(−)-N-Butylscopolamine bromide, Hyoscine N-butyl bromide, (−)-Scopolamine N-butyl bromide
Empirical Formula (Hill Notation):
C21H30BrNO4
CAS Number:
Molecular Weight:
440.37
MDL number:
PubChem Substance ID:
NACRES:
NA.24
Pricing and availability is not currently available.

grade

pharmaceutical primary standard

form

neat

CofA

certificate is enclosed in each package

mfr. no.

EDQM

Featured Industry

Pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Br-.HC@@12CC@H(CC@@(H)(C@3(H)OC@13H)N+2(C)CCCC)OC(=O)C@H(CO)c4ccccc4

InChI

1S/C21H30NO4.BrH/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14;/h5-9,15-20,23H,3-4,10-13H2,1-2H3;1H/q+1;/p-1/t15-,16-,17-,18+,19-,20+,22?;/m1./s1

InChI key

HOZOZZFCZRXYEK-GSWUYBTGSA-M

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the
issuing Pharmacopoeia.

Packaging

Unit quantity: 20 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference subtance catalogue.

Caution

Other Notes

Sales restrictions may apply.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

RIDADR

NONH for all modes of transport

WGK Germany

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
Marina Aloi et al.
Gastrointestinal endoscopy, 81(2), 420-427 (2014-08-15)
Small-bowel (SB) disease is a severe clinical entity among the phenotypes of Crohn's disease (CD). To assess sensitivity, specificity, and accuracy of magnetic resonance enterography (MRE), small-intestine contrast US (SICUS), and capsule endoscopy (CE) in the diagnosis of pediatric SB-CD....
Andrew A Plumb et al.
AJR. American journal of roentgenology, 203(4), W400-W407 (2014-09-24)
The purpose of this article is to describe the MRI findings associated with lymphoid nodular hyperplasia at MR enterography and test the ability of radiologists to differentiate healthy control subjects from patients with Crohn disease (CD). Ethical approval was granted...
K Mackway-Jones et al.
Emergency medicine journal : EMJ, 20(3), 267-267 (2003-05-16)
A short cut review was carried out to establish whether buscopan (hyoscine butylbromide) is better than analgesics at controlling pain in abdominal colic. A total of 31 papers were found using the reported search, of which none presented any evidence...
Guido N Tytgat
Drugs, 67(9), 1343-1357 (2007-06-06)
Abdominal cramping and pain is a frequent problem in the adult population of Western countries, with an estimated prevalence of < or =30%. Hyoscine butylbromide (scopolamine butylbromide) [Buscopan/Buscapina] is an antispasmodic drug indicated for the treatment of abdominal pain associated...
Timur H Kuru et al.
Journal of computer assisted tomography, 38(4), 558-564 (2014-04-16)
To compare 2 previously presented algorithms for extracting parameters from intravoxel incoherent motion (IVIM) studies and investigate them in the context of tissue differentiation. Magnetic resonance imaging (MRI) was performed in 23 patients without histologically proven prostate carcinoma (PCa) and...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

MilliporeSigma

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.